Boards

Management Board

Dominique Demolle

Dominique Demolle

CEO

Alvaro Pereira

Alvaro Pereira

CSO

Chantal Gossuin

Chantal Gossuin

COO

Dominique Demolle has served as Chief Executive Officer at Tools4Patient since its creation in 2013.

In 1989 she graduated from the Free University of Brussels with a PhD in Biochemistry and joined the Clinical Research Group of GD Searle Belgium. After directly managing clinical trials for 9 years she was promoted to a management position at Eli Lilly. Since then she has movedup the ranks and held positions with increasing leadership responsibilities. Her responsibilities progressed from the Lilly Indianapolis clinical research unit in the US and European Operational Staff management to the position of Associate Director of Global Early Phase Operations. In 2007 she co-founded Aepodia a Clinical Research Organization where she acted as CEO.

Alvaro Pereira has held the position of Chief Scientific Officer at Tools4Patient since its inception. He graduated from the Free University of Brussels with a PhD in Biochemistry in 1990 and continued his academic research as research fellow in the Bioorganic Chemistry and Neurophysiopathology departments. He started his career in the pharmaceutical industry in 1996 at Eli Lilly joining the Clinical Pharmacology Department. Throughout his industrial career he held the position of Clinical Pharmacologist with increasing responsibilities, from single pharmacological trials up to full Phase I clinical development for new CNS molecules. In 2007 he joined Aepodia where he took charge of the early clinical components of drug development from first-in-man administration up to Phase Ib/IIa – Proof of concept (POC) studies including biomarkers validation/development.

Chantal Gossuin has worked as Chief Operating Officer at Tools4Patient since its creation. She holds an Industrial Pharmacy Master’s degree gained at the Free University of Brussels. In 1993, she joined the Quality Control Department at Eli Lilly, Fegersheim. From 1995, she played different roles in the Clinical Trial Material Department at Eli Lilly where she was promoted to a management position in 1999. In 2006, she used her people management skills and clinical trial experience as Project Manager for the Drug Product Management and Industrialization Department at UCB, a biopharma company. After that she secured a position as Clinical Project Leader at Aepodia, a Contract Research Organization.

Scientific Committee

Jean Stephenne

Jean Stephenne

John Bloom

John Bloom

Marc Buyse

Marc Buyse

Sanjay Dube

Sanjay Dube

Alvaro Pereira

Alvaro Pereira

Jean Stephenne holds an MSc in chemistry and bioindustries from Gembloux Agro-Bio Tech and obtained an MBA in Management from U.C. Louvain. In 1974, he joined SmithKline-Rit, where he held positions with increasing leadership responsibilities throughout the Vaccines Division up to being promoted as President and General Manager of GlaxoSmithKline Biologicals. During his nearly 40 years at GSK, he steered the company through a series of mergers to create one of the leading global vaccine companies upon his retirement in 2012. Today Jean Stephenne continuously nurtures his wide experience through his involvement as chairmain in many companies. His experience has also led him to preside over the Walloon Union of Companies (the employers’ association of Wallonia) from 1997 to 2000.

 

John C. Bloom holds a B.S. degree in biology, doctorates in veterinary medicine and experimental hematology from the University of Pennsylvania. He completed his postdoctoral training at Jefferson Medical College. Dr Bloom served on the Faculty of the University of Pennsylvania School of Veterinary Medicine as Chief, Clinical Laboratory Medicine, before joining Smith Kline & French Laboratories. He later joined Lilly Research Laboratories as Head, Clinical Pathology, in the Toxicology Division, and subsequently moved to the Medical Division. As Distinguished Medical Fellow (Executive Director), Diagnostic and Experimental Medicine, he was responsible for laboratory, ECG, imaging and specimen banking support for global clinical development; and novel clinical biomarker discovery, validation and application in the Division of Translational Medicine and Pharmacogenomics. Dr. Bloom is a past president of the American Society for Veterinary Clinical Pathology; has authored several manuscripts, chapters, reviews and texts on toxicology and clinical biomarkers in drug development; and served on committees sponsored by the National Academy of Sciences, Institute of Medicine, Society of Toxicologic Pathology and PhRMA. Upon his retirement from Lilly in 2009 he established Bloom Consulting Services, LLC and has been appointed Consultant, Office of the Center Director, FDA. In the latter capacity he serves on Drug Advisory Committees and special FDA/NIH project assignments. Dr. Bloom serves on several Scientific Advisory Committees and holds adjunct academic appointments at the University of Pennsylvania and Purdue University.

Marc Buyse is founder of IDDI, Chairman of IDDI and Associate Professor of Biostatistics at the Universiteit Hasselt. He holds degrees in engineering and statistics from Brussels University (ULB), management from the Cranfield School of Management (Cranfield, UK) and a doctorate in biostatistics from Harvard University (Boston, MA). He was the recipient of several research fellowships in Belgium, the US and Japan. He was President of the International Society for Clinical Biostatistics, President of the Quetelet Society, and Fellow of the Society for Clinical Trials. He worked at the EORTC (European Organization for Research and Treatment of Cancer) in Brussels and at the Dana Farber Cancer Institute in Boston prior to founding IDDI in 1991.

Sanjay Dube holds an MD in Psychiatry from the King George’s Medical College. He started his clinical and academic carrier at Lafayette Clinic of the Wayne State University for a decade. Afterwards, he moved to the Western Psychiatric Institute and clinic at the University of Pittsburgh as Associate Professor of Psychiatry. In 2001 he joined also the Indiana University School of Medicine as Clinical  Professor of Psychiatry. He has received several teaching awards including the prestigious Nancy Roeske Award from the American Psychiatric Association and the excellence in teaching from the Association of Academic Psychiatry. In 2014, Dr. Dube was appointed as a Consulting Associate Professor of Psychiatry at the Stanford University School of Medicine and Behavioural Sciences and continues to hold Adjunct appointments at IU School of Medicine and the University of Pittsburgh.  Dr Dube has made a strong carrier in the pharmaceutical industry, starting at Eli Lilly and a company in 2001 as Medical Director of Phase 2 and 3 compounds and finishing as Senior Medical Fellow where he has been recognized as a talented neuropsychiatrist dedicated to developing novel medications for severe mental illnesses.  Additional he has lead the Phase 2 program for chronic pain at Theravance Biopharma and recently he has joined the Avanir where is responsible of the CNS pipeline as Vice President Clinical Development.  Dr Dube is widely published and is a member of several International Organizations.

Alvaro Pereira has held the position of Chief Scientific Officer at Tools4Patient since its inception. He graduated from the Free University of Brussels with a PhD in Biochemistry in 1990 and continued his academic research as research fellow in the Bioorganic Chemistry and Neurophysiopathology departments. He started his career in the pharmaceutical industry in 1996 at Eli Lilly joining the Clinical Pharmacology Department. Throughout his industrial career he worked as a Clinical Pharmacologist with increasing responsibilities from single pharmacological trials up to full Phase I clinical development for new CNS molecules. In 2007 he joined Aepodia where he took charge of the early clinical components of drug development from first-in-man administration up to Phase Ib/IIa – Proof of concept (POC) studies including biomarkers validation/development.

Company Board

Marc Ponnet

Marc Ponnet

Nicole Van de Gucht

Nicole Van de Gucht

Mike Van Ganse

Mike Van Ganse

John Hall

John Hall

Marc Deschamps

Marc Deschamps

Dominique Demolle

Dominique Demolle

Marc Ponnet graduated from HOGENT in biotechnology and in tax system from EHSAL. He started his career at Général de Banque and then founded B-Connected, a call-centre based in Brussels and employing about 300 people. He also owns Nixxis, a company dedicated to the development of software for call- and contact centers also based in Brussels. His entrepreneurial activities brought him to invest in technological companies such as Softkinetic and Swingguru and also in several real-estate projects. His broad business background has established him as a successful entrepreneur.

Nicole Van de Gucht graduated from U.C. Louvain-la-Neuve as lawyer and specialized in Financial and Economic Law from UGent. She also holds a master degree in management from the Flemish Institute of Management. In 1989, she acted as consultant for different US Executive Search firms based in Brussels and Paris during 9 years. After what she has operated as Human Ressource Director at Walibi Group for 4 years. In 2002, she joined American Standard as Staffing Director EAME & Latin America and worked at Arrow Electronics based in Milan with a similar management position. She is now an administrator of the family foundation and Jean XXIII College.

After his studies at the Solvay Business School of Management in Brussels, Mike started his career in the healthcare sector. Mike always worked in consumer health and gained a solid experience in building strong international brands. He first worked for almost 10 years with Novartis in the Benelux, in the US and at headquarters in Switzerland. He then moved to France for 4 years to join Roche and later Bayer following the divestment of the global Roche consumer health division. He returned to Belgium in 2007 to become Chief Marketing & Innovation of Omega Pharma group. In 2009 he became founder of jeCare, a start-up that launched the brand Excilor, an innovative treatment in nail fungus. Excilor became category leader in over 10 countries in just 3 years and was sold at the end of 2012 to a major European OTC company. Since then, Mike has remained active in the healthcare industry as manager/investor.      

Dr. John Hall co-founded Leader Partners in 2008, a platform for the delivery of advisory services to investors and management in the biotechnology, pharmaceutical and contract research sectors. He has over 40 years’ international experience in these industries at a senior executive level. Prior to setting up Leader Partners, John was President, European Operations at AAIPharma Inc. where he was responsible for the development and expansion of preclinical and clinical services across Europe and South Africa. He has also served as Senior Vice President of Corporate Development for Quintiles Transnational Corp. and in senior R&D positions in GD Searle, Monsanto, Inveresk Research and Roche. John Hall has a Ph.D. in pharmacology. He has been an Honorary Lecturer in Management Studies at St. Andrew’s University and has been an invited speaker and chairman at conferences in the United States, Europe and Asia.

Marc Deschamps is graduated from U.C. Leuven as an engineer and has a degree both in Law and in Economics. In 1979, he joined Société Générale de Belgique and, after attending the SLOAN program at Stanford University in 1984-85, he created a development capital firm dedicated to SMEs. In 1992, Marc Deschamps bought out a service company that he developed in more than twenty countries. In 2000, he created Investparks, dedicated to the development of science parks linked to universities in emerging countries and, in 2006, he launched Exego, specializing in corporate governance services. Marc Deschamps is Affiliate Professor at HEC-ULg and lecturer at Solvay Brussels School (ULB-Brussels). Marc Deschamps is also a founding director of the Forum Francophone des Affaires in Belgium, of the Association du Management and of Guberna (the Belgian corporate governance association).

Dominique Demolle has served as Chief Executive Officer at Tools4Patient since its creation in 2013.

In 1989 she graduated from the Free University of Brussels with a PhD in Biochemistry and joined the Clinical Research Group of GD Searle Belgium. After directly managing clinical trials for 9 years she was promoted to a management position at Eli Lilly. Since then she has held positions with increasing leadership responsibility. Her responsibilities progressed from the Lilly Indianapolis clinical research unit in the US and European Operational Staff management to the position of Associate Director of Global Early Phase Operations. In 2007 she co-founded Aepodia a Clinical Research Organization where she worked as CEO.

Investors

Tools4Patient has received Grants from the Walloon Region and has completed its first fundraising in Septembre 2014 and a second one in April 2015.

This first round includes new investors as Jean Stephenne, Mike VanGanse, Nicole Van de Gucht and InvestCo.

Funding will be devoted to Research & Development activities for the first two platforms.


Nicole Van de Gucht

Nicole Van de Gucht

Jean Stephenne

Jean Stephenne

Mike Van Ganse

Mike Van Ganse

InvestCo

InvestCo

Nicole Van de Gucht graduated from U.C. Louvain-la-Neuve as lawyer and specialized in Financial and Economic Law from UGent. She also holds a Masters degree in management from the Flemish Institute of Management. Starting in 1989, she acted for 9 years as consultant for several US Executive Search firms based in Brussels and Paris. She then worked has operated as Human Ressource Director at Walibi Group for 4 years. In 2002, she joined American Standard as Staffing Director EAME & Latin America and worked at Arrow Electronics based in Milan with a similar management position. She is now an administrator of the family foundation and also Jean XXIII College.

Jean Stephenne holds an MSc in chemistry and bioindustries from Gembloux Agro-Bio Tech and obtained an MBA in Management from U.C. Louvain. In 1974, he joined SmithKline-R.I.T, where he held positions with increasing leadership responsibilities throughout the Vaccines Division up to being promoted as President and General Manager of GlaxoSmithKline Biologicals. During his nearly 40 years at GSK, he steered the company through a series of mergers to create one of the leading global vaccine companies upon his retirement in 2012. Today Jean Stephenne continuously nurtures his wide experience through his involvement in many companies. His experience has also led him to preside over the Walloon Union of Companies (the employers’ association of Wallonia) from 1997 to 2000.

After his studies at the Solvay Business School of Management in Brussels, Mike started his career in the healthcare sector. Mike has worked in consumer health and gained a solid experience in building strong international brands. He first worked for almost 10 years with Novartis in the Benelux, the US and at headquarters in Switzerland. He then moved to France for 4 years to join Roche and later Bayer following the divestment of the global Roche consumer health division. He returned to Belgium in 2007 to become Chief Marketing & Innovation Officer of Omega Pharma group. In 2009 he became founder of jeCare, a start-up that launched the brand Excilor, an innovative treatment in nail fungus. Excilor became a category leader in over 10 countries in just 3 years and was sold at the end of 2012 to a major European OTC company. Since then, Mike has remained active in the healthcare industry as manager/investor.      

InvestCo is an investment company founded by private investors earger to invest in innovative Belgian ’s companies having an international ambition.
InvestCo elected to  invest in Tools4Patient because of their innovative R&D with high potential of development  and their experienced and enthusiastic team. ​

Menu

Tools 4 Patient